FGF15/19 efficiently increases insulin sensitivity and is currently utilized to treat major metabolic illnesses such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH). Here, INS is linked to metabolic dysfunction-associated steatohepatitis.